Hematopathology Eligible or CAR-t Cell TreatmentNCT04328298
French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)
An observational study of Hematopathology Eligible or CAR-t Cell Treatment, run by The Lymphoma Academic Research Organisation at 36 sites in France.
Trial summary
This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment. Read more about this study
- Who is it for?
- Ages 0 to 99 years
- Conditions the study is for
- Hematopathology Eligible or CAR-t Cell Treatment
- How many people
- 5,000 participants
- Where
- 36 sitesFrance
- Study dates
- 19 Dec 2019to 19 Dec 2038
- How long will I take part?
- 15 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 99 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patient eligible for a treatment with CAR-T for an hematological malignancy
Who may be able to join
- Retrospective inclusion :
- Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center
- If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive
- Prospective inclusion :
- Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center.
- Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019
Show all 9Show fewer
- Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a qualified center according to the ministerial order of 8 August 2019
- If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive.
- Exclusion Criteria Patient not registered with the social security in France
Who cannot join
None listed.
Trial locations and contacts
36 sites in 1 country. Contact the study team or a site near you to ask about taking part.
36 sites in 1 country
France36 sites, 36 recruiting
- Recruiting
CHU d'Amiens - Hôpital Sud
Amiens
Magalie JORIS, MD, +33 (0)3 22 45 60 00, joris.magalie@chu-amiens.fr
- Recruiting
CHU Angers
Angers
Aline TANGUY-SCHMIDT, MD, alschmidt@chu-angers.fr
- Recruiting
CHRU Besançon - Hôpital Minjoz
Besançon
Adrien CHAUCHET, MD
- Recruiting
CHU de Brest - Hôpital du Morvan
Brest
Adrian TEMPESCUL, MD, adrian.tempescul@chu-brest.fr
- Recruiting
Institut d'Hématologie de Basse Normandie
Caen
Ghandi DAMAJ, Pr, damaj-gl@chu-caen.fr
- Recruiting
CHU d'Estaing
Clermont-Ferrand
Jacques-Olivier BAY, Pr, +33 (0)4 73 75 00 65, jobay@chu-clermontferrand.fr
- Recruiting
APHP - Hôpital Henri Mondor
Créteil
Fabien LE BRAS, MD, +33 (0)1 49 83 65 05, fabien.le-bras@aphp.fr
- Recruiting
CHU de Dijon
Dijon
Olivier CASASNOVAS, MD, +33 (0)3 80 29 50 41, olivier.casasnovas@chu-dijon.fr
- Recruiting
CHU de Grenoble
La Tronche
Sylvain CARRAS, MD, +33 (0)4 76 76 57 55, scarras@chu-grenoble.fr
- Recruiting
CHRU de Lille - Hôpital Claude Hurriez
Lille
Ibrahim YAKOUB-AGHA, Pr, +33 (0)3 20 44 42 84, ibrahim.yakoubagha@chru-lille.fr
- Recruiting
Hôpital Dupuytren
Limoges
Julie ABRAHAM, MD, +33 (0)5 55 05 66 51, julie.abraham@chu-limoges.fr
- Recruiting
Centre Léon Bérard
Lyon
- Recruiting
Institut d'Hématologie et d'Oncologie Pédiatrique (IHOP)
Lyon
Yves BERTRAND, Pr, yves.bertrand@ihope.fr
- Recruiting
Hôpital de la Timone
Marseille
Arthur STERIN, MD, arthur.sterin@aph-m.fr
- Recruiting
Institut Paoli Calmette
Marseille
Aude Collignon, MD
- Recruiting
CHU de Montpellier
Montpellier
Guillaume CARTRON, Pr, +33(0)4 67 33 67 33, guillaume.cartron@orange.fr
- Recruiting
CHU de Nantes - Hôtel Dieu
Nantes
Thomas GASTINNE, MD, +33 (0)2 40 08 33 02, thomas.gastinne@chu-nantes.fr
- Recruiting
CHU de Nice
Nice
Michaël LOSCHI, MD, +33 (0)4 92 03 90 25, loschi.m@chu-nice.fr
- Recruiting
APHP - Hôpital Cochin
Paris
Jérémie ZERBIT, Dr, jeremie.zerbit@aphp.fr
- Recruiting
APHP - Hôpital La Pitié Salpêtrière
Paris
Sylvain CHOQUET, MD, +33 (0)1 42 16 28 26, sylvain.choquet@aphp.fr
- Recruiting
APHP - Hôpital Necker
Paris
Olivier HERMINE, Pr, +33 (0)1 44 49 51 98, olivier.hermine@aphp.fr
- Recruiting
APHP - Hôpital Saint Antoine
Paris
Mohamad MOHTY, Pr, +33 (0)1 49 28 26 20, mohamad.mohty@inserm.fr
- Recruiting
APHP - Hôpital Saint Louis
Paris
Catherine THIEBLEMONT, Pr, +33 (0) 1 42 49 98 37, catherine.thieblemont@aphp.fr
- Recruiting
APHP - Hôpital Universitaire Robert Debré
Paris
André BARUCHEL, Pr, +33 (0)1 40 03 53 88, andre.baruchel@aphp.fr
- Recruiting
Centre Francois Magendie
Pessac
Kamal BOUABDALLAH, MD, +33 (0)5 57 65 65 11, kamal.bouabdallah@chu-bordeaux.fr
- Recruiting
Centre Hospitalier Lyon Sud
Pierre-Bénite
Emmanuel BACHY, Pr, +33 (0)4 78 86 43 01, emmanuel.bachy@chu-lyon.fr
- Recruiting
Hôpital de la Milétrie - CHU de Poitiers
Poitiers
Xavier LELEU, Pr, +33 (0)5 49 44 46 89, xavier.leleu@chu-poitiers.fr
- Recruiting
CHU de Rennes - Hôpital Pontchaillou
Rennes
Thierry LAMY-DE-LA-CHAPELLE, Pr, +33 (0)2 99 28 42 91, thierry.lamy.de.la.chapelle@chu-rennes.fr
- Recruiting
Centre Henri Becquerel
Rouen
Fabrice JARDIN, Pr, +33 (0)2 32 08 24 65, fabrice.jardin@chb.unicancer.fr
- Recruiting
CHU de Rouen Normandie
Rouen
Nimrod BUCHBINDER, MD, Nimrod.Buchbinder@chu-rouen.fr
- Recruiting
Institut de Cancérologie Hématologie Universitaire de Saint Etienne
Saint-Priest-en-Jarez
Ludovic FOUILLET, MD, ludovic.fouillet@icloire.fr
- Recruiting
ICANS (Institut de Cancérologie Strasbourg Europe)
Strasbourg
Blandine GUFFROY, MD, b.guffroy@icans.eu
- Recruiting
Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O)
Toulouse
Pierre BORIES, MD, +33 (0)5 31 15 65 14, bories.pierre@iuct-oncopole.fr
- Recruiting
CHU Bretonneau
Tours
Emmanuel GYAN, MD, +33 (0)2 47 47 37 12, e.gyan@chu-tours.fr
- Recruiting
CHU Brabois
Vandœuvre-lès-Nancy
Marie-Thérèse RUBIO, Pr, +33 (0)3 83 15 32 82, m.rubio@chru-nancy.fr
Marie-Thérèse RUBIO, Pr
- Recruiting
Gustave Roussy Cancer Campus
Villejuif
Cristina CASTILLA LLORENTE, MD, +33 (0)1 42 11 42 39, cristina.castilla-llorente@gustaveroussy.fr
About this study
This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.
What is being measured
The primary outcome is the main question the study is designed to answer.
overall survival from eligibility
Measured: 15 years
Overall survival from administration
Measured: 15 years
complete response rate
Measured: 15 years
Progression free survival
Measured: 15 years
Duration of response
Measured: 15 years
Delays between patient eligibility and CAR-T treatment
Measured: 15 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Mar 2020
- Study start19 Dec 2019
- Primary completion19 Dec 2038 (estimated)
- Study completion19 Dec 2038 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Hematopathology Eligible or CAR-t Cell TreatmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 5,000 participants (estimated)
- Target duration
- 15 Years
Sponsor and investigators
- Lead sponsor
- The Lymphoma Academic Research Organisation
- Sponsor type
- University, hospital or other
- Collaborators
- Gilead Sciences, Novartis, Bristol-Myers Squibb
- Responsible party
- Sponsor
- Investigators
- Steven LE GOUILL, Pr, Principal investigator, Institut CurieRoch HOUOT, Pr, Principal investigator, CHU Pontchaillou
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04328298
- Sponsor's protocol ID
- DESCAR-T
- Status last verified
- Mar 2026
- First submitted
- 27 Mar 2020
- Last updated
- 4 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Manson G, Di Blasi R, Houot R, Morschhauser F, Cartron G, Gastinne T, Blaise D, Gros FX, Bories P, Le Bras F, Rubio MT, Mohty M, Bay JO, Guidez S, Castilla Llorente C, Jardin F, Durand A, Guffroy B, Loschi M, Drieu La Rochelle L, Abraham J, Chauchet A, Herbreteau L, Choquet S, Joris M, Carras S, Damaj GL, Decroocq J, Aline TS, Hermine O, Nicolas-Virelizier E, Gat E, Le Gouill S, Bachy E, Dulery R. Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Bone Marrow Transplant. 2026 Aug 21. doi: 10.1038/s41409-026-03001-0. Online ahead of print.
PubMed 42629429Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M, Malard F, Petillon MO, Manier S, Yakoub-Agha I, Caillot D, Lafon I, Leleu X, Moya N, Royer B, Schiano De Colella JM, Brisou G, Touzeau C, Perrot A, Bories P, Vincent L, Guedon H, Decaux O, Ferment B, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Avet-Loiseau H, Moreau P, Arnulf B. Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. Blood Adv. 2026 Feb 24;10(4):1324-1333. doi: 10.1182/bloodadvances.2025017597.
PubMed 40966637Sesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, Brisou G, Gros FX, le Bras F, Bories P, Choquet S, Rubio MT, Iacoboni G, O'Reilly M, Casasnovas RO, Bay JO, Mohty M, Joris M, Abraham J, Castilla Llorente C, Loschi M, Carras S, Chauchet A, La Rochelle LD, Hermine O, Guidez S, Cony-Makhoul P, Fogarty P, Le Gouill S, Morschhauser F, Gastinne T, Cartron G, Subklewe M, Locke FL, Sanderson R, Barba P, Houot R, Bachy E. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J Hematol Oncol. 2024 Aug 6;17(1):61. doi: 10.1186/s13045-024-01579-w.
PubMed 39107847Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Llorente CC, Choquet S, Casasnovas RO, Mohty M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Deau-Fischer B, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022 Oct;28(10):2145-2154. doi: 10.1038/s41591-022-01969-y. Epub 2022 Sep 22.
PubMed 36138152
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)
- ClinicalTrials.gov ID
- NCT04328298
- Acronym / sponsor ID
- DESCAR-T
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- The Lymphoma Academic Research OrganisationUniversity, hospital or other
- Collaborators
- Gilead Sciences, Novartis, Bristol-Myers Squibb
- Study start
- 19 Dec 2019 (actual)
- Primary completion
- 19 Dec 2038 (estimated)
- Study completion
- 19 Dec 2038 (estimated)
- First posted
- 31 Mar 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 15 Years
Who may qualify
- Ages
- 0 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patient eligible for a treatment with CAR-T for an hematological malignancy
Key inclusion criteria (9 listed)
- Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center
- If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive
- Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center.
- Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019
- Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a qualified center according to the ministerial order of 8 August 2019
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
overall survival from eligibility
Time frame: 15 years
Overall survival from administration
Time frame: 15 years
complete response rate
Time frame: 15 years
Progression free survival
Time frame: 15 years
Duration of response
Time frame: 15 years
Delays between patient eligibility and CAR-T treatment
Time frame: 15 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2026.
- Derived from this study: PubMed 42629429Manson G, Di Blasi R, Houot R, Morschhauser F, Cartron G, Gastinne T, Blaise D, Gros FX, Bories P, Le Bras F, Rubio MT, Mohty M, Bay JO, Guidez S, Castilla Llorente C, Jardin F, Durand A, Guffroy B, Loschi M, Drieu La Rochelle L, Abraham J, Chauchet A, Herbreteau L, Choquet S, Joris M, Carras S, Damaj GL, Decroocq J, Aline TS, Hermine O, Nicolas-Virelizier E, Gat E, Le Gouill S, Bachy E, Dulery R. Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Bone Marrow Transplant. 2026 Aug 21. doi: 10.1038/s41409-026-03001-0. Online ahead of print.
- Derived from this study: PubMed 40966637Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M, Malard F, Petillon MO, Manier S, Yakoub-Agha I, Caillot D, Lafon I, Leleu X, Moya N, Royer B, Schiano De Colella JM, Brisou G, Touzeau C, Perrot A, Bories P, Vincent L, Guedon H, Decaux O, Ferment B, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Avet-Loiseau H, Moreau P, Arnulf B. Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. Blood Adv. 2026 Feb 24;10(4):1324-1333. doi: 10.1182/bloodadvances.2025017597.
- Derived from this study: PubMed 39107847Sesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, Brisou G, Gros FX, le Bras F, Bories P, Choquet S, Rubio MT, Iacoboni G, O'Reilly M, Casasnovas RO, Bay JO, Mohty M, Joris M, Abraham J, Castilla Llorente C, Loschi M, Carras S, Chauchet A, La Rochelle LD, Hermine O, Guidez S, Cony-Makhoul P, Fogarty P, Le Gouill S, Morschhauser F, Gastinne T, Cartron G, Subklewe M, Locke FL, Sanderson R, Barba P, Houot R, Bachy E. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J Hematol Oncol. 2024 Aug 6;17(1):61. doi: 10.1186/s13045-024-01579-w.
- Derived from this study: PubMed 36138152Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Llorente CC, Choquet S, Casasnovas RO, Mohty M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Deau-Fischer B, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022 Oct;28(10):2145-2154. doi: 10.1038/s41591-022-01969-y. Epub 2022 Sep 22.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Steven LE GOUILL, Pr principal investigator
Institut Curie
Roch HOUOT, Pr principal investigator
CHU Pontchaillou
36 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hematopathology Eligible or CAR-t Cell Treatment, run by The Lymphoma Academic Research Organisation at 36 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 36 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Karine Danno (+33 (04) 72 66 93 33, descar-t@lysarc.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
overall survival from eligibility (time frame: 15 years). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04328298, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2026.